A quantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects

Drug Development Research

Volumn 73, Issue 4, 2012, Pages 196-213

  Spiros, Athan ^a   Roberts, Patrick ^a,b   Geerts, Hugo ^a,c  

^a In Silico Biosciences   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Schizophrenia EPS; Schizophrenia PANSS; Simulation; Systems pharmacology

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SERTINDOLE;

AKATHISIA; ANTIDROMIC STIMULATION; ARTICLE; BRAIN CORTEX; COMPUTER MODEL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFICACY; DYSTONIA; ENZYME ACTIVATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MUSCLE HYPERTONIA; NEUROBIOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TREMOR;

EID: 84862896528     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21008     Document Type: Article

References (113)

1. Abdallah L, Bonasera SJ, Hopf FW, O'Dell L, Giorgetti M, Jongsma M, Carra S, Pierucci M, Di Giovanni G, Esposito E, et al. 2009. Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J Neurosci 29:8156-8165.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, et al. 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109. (Pubitemid 30460780)
3. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, et al. 2002. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719. (Pubitemid 37465776)
4. Andree B, Halldin C, Vrijmoed-de Vries M, Farde L. 1997. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 131:339-345. (Pubitemid 27348699)
5. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. 2008. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197:229-235.
6. Awouters FH, Lewi PJ. 2007. Forty years of antipsychotic Drug research - from haloperidol to paliperidone - with Dr. Paul Janssen. Arzneimittelforschung 57:625-632. (Pubitemid 350075407)
7. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. 1996. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35-46. (Pubitemid 26047184)
8. Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM. 2003. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res 959:58-67. (Pubitemid 35435406)
9. Bamford NS, Robinson S, Palmiter RD, Joyce JA, Moore C, Meshul CK. 2004. Dopamine modulates release from corticostriatal terminals. J Neurosci 24:9541-9552. (Pubitemid 39441508)
10. Ban TA. 2007. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 3:495-500. (Pubitemid 350028014)
11. Bargas J, Howe A, Eberwine J, Cao Y, Surmeier DJ. 1994. Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci 14(11 Pt 1):6667-6686.
12. Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Kufferle B, Asenbaum S, Brucke T, Rao ML, Kasper S. 2001. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl) 157:236-242. (Pubitemid 32905564)
13. Bernardo M, Parellada E, Lomena F, Catafau AM, Font M, Gomez JC, Lopez-Carrero C, Gutierrez F, Pavia J, Salamero M. 2001. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res 107:87-97. (Pubitemid 32786941)
14. Blomeley CP, Bracci E. 2009. Serotonin excites fast-spiking interneurons in the striatum. Eur J Neurosci 29:1604-1614.
15. Bonsi P, Cuomo D, Ding J, Sciamanna G, Ulrich S, Tscherter A, Bernardi G, Surmeier DJ, Pisani A. 2007. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32:1840-1854. (Pubitemid 47076377)
16. Braga MF, Aroniadou-Anderjaska V, Manion ST, Hough CJ, Li H. 2004. Stress impairs alpha(1A) adrenoceptor-mediated noradrenergic facilitation of GABAergic transmission in the basolateral amygdala. Neuropsychopharmacology 29:45-58. (Pubitemid 38068013)
17. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS. 2003. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420. (Pubitemid 41070915)
18. Brown P, Mazzone P, Oliviero A, Altibrandi MG, Pilato F, Tonali PA, Di Lazzaro V. 2004. Effects of stimulation of the subthalamic area on oscillatory pallidal activity in Parkinson's disease. Exp Neurol 188:480-490. (Pubitemid 38891608)
19. Burgyone K, Aduri K, Ananth J, Parameswaran S. 2004. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des 10:2239-2248. (Pubitemid 38832766)
20. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. 1998. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur J Neurosci 10:2887-2895. (Pubitemid 29073961)
21. Carr DB, Cooper DC, Ulrich SL, Spruston N, Surmeier DJ. 2002. Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci 22:6846-6855. (Pubitemid 35379142)
22. Cragg SJ, Hille CJ, Greenfield SA. 2000. Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J Neurosci 20:8209-8217.
23. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564. (Pubitemid 36682312)
24. Dayalu P, Chou KL. 2008. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 9:1451-1462. (Pubitemid 352005909)
25. De Deurwaerdere P, Stinus L, Spampinato U. 1998. Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 18:6528-6538. (Pubitemid 28373254)
26. Falk T, Xie JY, Zhang S, Kennedy J, Bennett J, Yool AJ, Sherman SJ. 2008. Over-expression of the potassium channel Kir2.3 usingthe dopamine-1 receptor promoter selectively inhibits striatal neurons. Neuroscience 155:114-127.
27. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G. 1990. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213-219. (Pubitemid 20086672)
28. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
29. Foehring RC. 1996. Serotonin modulates N- and P-type calcium currents in neocortical pyramidal neurons via a membrane-delimited pathway. J Neurophysiol 75:648-659. (Pubitemid 26073463)
30. Gabel LA, Nisenbaum ES. 1998. Biophysical characterization and functional consequences of a slowly inactivating potassium current in neostriatal neurons. J Neurophysiol 79:1989-2002. (Pubitemid 28183333)
31. Gabel LA, Nisenbaum ES. 1999. Muscarinic receptors differentially modulate the persistent potassium current in striatal spiny projection neurons. J Neurophysiol 81:1418-1423. (Pubitemid 29272458)
32. Geddes J, Freemantle N, Harrison P, Bebbington P. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371-1376.
33. Geerts H. 2009. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23:915-926.
34. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. 2011. A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 36:1903-1911.
35. Goto Y, O'Donnell P. 2001. Synchronous activity in the hippocampus and nucleus accumbens in vivo. J Neurosci 21:RC131.
36. Grace AA, Bunney BS. 1984a. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890. (Pubitemid 15224432)
37. Grace AA, Bunney BS. 1984b. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4:2866-2876. (Pubitemid 15224431)
38. Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. 2009. Optical deconstruction of parkinsonian neural circuitry. Science 324:354-359.
39. Green MF, Nuechterlein KH. 2004. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 72:1-3. (Pubitemid 39452899)
40. Gruber AJ, O'Donnell P. 2009. Bursting activation of prefrontal cortex drives sustained up states in nucleus accumbens spiny neurons in vivo. Synapse 63:173-180.
41. Gruber AJ, Solla SA, Surmeier DJ, Houk JC. 2003. Modulation of striatal single units by expected reward: a spiny neuron model displaying dopamine-induced bistability. J Neurophysiol 90:1095-1114. (Pubitemid 37092590)
42. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. 1997. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54:225-232. (Pubitemid 27132051)
43. Hazlett EA, Buchsbaum MS, Zhang J, Newmark RE, Glanton CF, Zelmanova Y, Haznedar MM, Chu KW, Nenadic I, Kemether EM, et al. 2008. Frontal-striatal- thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating. Neuroimage 42:1164-1177.
44. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ. 2000. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3- calcineurin-signaling cascade. J Neurosci 20:8987-8995. (Pubitemid 32042899)
45. Hines ML, Carnevale NT. 1997. The NEURON simulation environment. Neural Comput 9:1179-1209. (Pubitemid 127469144)
46. Hippius H. 1999. A historical perspective of clozapine. J Clin Psychiatry 60(Suppl. 12):22-23. (Pubitemid 29283178)
47. Hollerman JR, Grace AA. 1989. Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 96:82-88. (Pubitemid 19003454)
48. Hollerman JR, Grace AA. 1992. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 590:291-299.
49. Howes OD, Kapur S. 2009. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35:549-562.
50. Jann MW. 1991. Clozapine. Pharmacotherapy 11:179-195.
51. John CE, Budygin EA, Mateo Y, Jones SR. 2006. Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse. J Neurochem 96:267-282.
52. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, et al. 2006a. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 187:222-228. (Pubitemid 44015616)
53. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A. 2006b. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29:409-416. (Pubitemid 43063297)
54. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. 2009. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:627-643.
55. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. 1997. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154:1525-1529. (Pubitemid 27471344)
56. Kapur S, Cho R, Jones C, McKay G, Zipursky RB. 1999a. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol Psychiatry 45:1217-1220. (Pubitemid 29236564)
57. Kapur S, Zipursky RB, Remington G. 1999b. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293. (Pubitemid 29077120)
58. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N. 2011. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31:349-355.
59. Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. 2003. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch Gen Psychiatry 60:311-319. (Pubitemid 36307443)
60. Kumar R, Sachdev PS. 2009. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22:293-299.
61. Kuzhikandathil EV, Oxford GS. 2002. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzaze pine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol 62:119-126.
62. la Fougere C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K, Hahn K, Moller HJ, Dresel S. 2005. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med 46:1028-1033. (Pubitemid 43733520)
63. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J. 2001. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115-120. (Pubitemid 32947054)
64. Laughren T, Levin R. 2006. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 32:220-222.
65. Law-Tho D, Hirsch JC, Crepel F. 1994. Dopamine modulation of synaptic transmission in rat prefrontal cortex: an in vitro electrophysiological study. Neurosci Res 21:151-160.
66. Lieberman JA. 2007. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 68:e04.
67. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. 2008. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
68. Llinas RR. 2000. Mapping brain terrain. Neurobiol Dis 7:499-500.
69. Lodge DJ, Grace AA. 2007. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424-11430. (Pubitemid 47621327)
70. Lodge DJ, Grace AA. 2008. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox Res 14:97-104.
71. Magnin M, Morel A, Jeanmonod D. 2000. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 96:549-564. (Pubitemid 30136320)
72. Maina FK, Mathews TA. 2010. A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem Neurosci 1:450-462.
73. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. 2004. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825. (Pubitemid 38625334)
74. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD. 2001. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105:379-392. (Pubitemid 32728122)
75. Matsui-Sakata A, Ohtani H, Sawada Y. 2005. Pharmacokineticpharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 20:187-199.
76. Meltzer HY. 1995. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64-75.
77. Mermelstein PG, Song WJ, Tkatch T, Yan Z, Surmeier DJ. 1998. Inwardly rectifying potassium (IRK) currents are correlated with IRK subunit expression in rat nucleus accumbens medium spiny neurons. J Neurosci 18:6650-6661. (Pubitemid 28387997)
78. Minabe Y, Shirayama Y, Hashimoto K, Routledge C, Hagan JJ, Ashby CR Jr. 2004. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 52:20-28. (Pubitemid 38316267)
79. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR. 2003. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116:107-117. (Pubitemid 36110438)
80. Muller-Vahl KR, Berding G, Kolbe H, Meyer GJ, Hundeshagen H, Dengler R, Knapp WH, Emrich HM. 2000. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand 101:165-171.
81. Murer MG, Tseng KY, Kasanetz F, Belluscio M, Riquelme LA. 2002. Brain oscillations, medium spiny neurons, and dopamine. Cell Mol Neurobiol 22:611-632. (Pubitemid 36169211)
82. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. 1993. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235. (Pubitemid 23091497)
83. Nyberg S, Farde L, Bartfai A, Halldin C. 1995. Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol 10:221-227.
84. Nyberg S, Dencker SJ, Malm U, Dahl ML, Svenson JO, Halldin C, Naskashima Y, Farde L. 1998. D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol 1:95-101. (Pubitemid 128538369)
85. Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L. 2002. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162:37-41. (Pubitemid 34639554)
86. Pani L, Pira L, Marchese G. 2007. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 22:267-275. (Pubitemid 47096691)
87. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107. (Pubitemid 47517511)
88. Perez-Rosello T, Figueroa A, Salgado H, Vilchis C, Tecuapetla F, Guzman JN, Galarraga E, Bargas J. 2005. Cholinergic control of firing pattern and neurotransmission in rat neostriatal projection neurons: role of CaV2.1 and CaV2.2 Ca2+ channels. J Neurophysiol 93:2507-2519. (Pubitemid 40570834)
89. Porras G, De Deurwaerdere P, Moison D, Spampinato U. 2003. Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 17:771-781. (Pubitemid 36315247)
90. Rhodes PA, Llinas RR. 2001. Apical tuft input efficacy in layer 5 pyramidal cells from rat visual cortex. J Physiol 536(Pt 1):167-187. (Pubitemid 32952228)
91. Sachdev P, Kruk J. 1994. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 51:963-974. (Pubitemid 24371866)
92. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. 2011. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 25:829-845.
93. Scarr E, Keriakous D, Crossland N, Dean B. 2006. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci 78:1231-1237.
94. Shen W, Hamilton SE, Nathanson NM, Surmeier DJ. 2005. Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci 25:7449-7458.
95. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, et al. 2000. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180.
96. Slutsky I, Wess J, Gomeza J, Dudel J, Parnas I, Parnas H. 2003. Use of knockout mice reveals involvement of M2-muscarinic receptors in control of the kinetics of acetylcholine release. J Neurophysiol 89:1954-1967. (Pubitemid 36444251)
97. Spiros A, Carr R, Geerts H. 2010. Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr Dis Treat 6:589-603.
98. Sugita S, Uchimura N, Jiang ZG, North RA. 1991. Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain. Proc Natl Acad Sci USA 88:2608-2611. (Pubitemid 21916467)
99. Swinney DC, Anthony J. 2011. How were new medicines discovered? Nat Rev Drug Discov 10:507-519.
100. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L. 2004. A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl) 175:148-153. (Pubitemid 39222344)
101. Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F, Farde L. 2000. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 148:400-403. (Pubitemid 30169758)
102. Tang TS, Bezprozvanny I. 2004. Dopamine receptor-mediated Ca(2+) signaling in striatal medium spiny neurons. J Biol Chem 279:42082-42094.
103. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. 2002. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 162:42-49. (Pubitemid 34639555)
104. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA. 1997. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484. (Pubitemid 27517576)
105. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. 1998. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155:505-508. (Pubitemid 28207446)
106. Turner JA, Smyth P, Macciardi F, Fallon JH, Kennedy JL, Potkin SG. 2006. Imaging phenotypes and genotypes in schizophrenia. Neuroinformatics 4:21-49.
107. Van Oekelen D, Luyten WH, Leysen JE. 2003. Ten years of antisense inhibition of brain G-protein-coupled receptor function. Brain Res Brain Res Rev 42:123-142. (Pubitemid 36549172)
108. Wiesel FA, Farde L, Halldin C. 1989. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET. Acta Psychiatr Scand Suppl 352:30-34. (Pubitemid 19247022)
109. Williams GV, Goldman-Rakic PS. 1995. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572-575.
110. Wirshing WC. 2001. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62(Suppl. 21):15-18. (Pubitemid 32937573)
111. Wolf W. 2003. DU-127090 Solvay/H Lundbeck. Curr Opin Investig Drugs 4:72-76.
112. Wong EH, Tarazi FI, Shahid M. 2010. The effectiveness of multitarget agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol Ther 126:173-185.
113. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. 2002. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259. (Pubitemid 34692591)